Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 3/20 | 0.82 |
| ▸ | DRD2 | P14416 | 1/20 | 0.58 |
| ▸ | HRH1 | P35367 | 1/20 | 0.58 |
| ▸ | KDM1A | O60341 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7607241 | 1.00 | SLC6A1 (0.82) | SLC6A1DRD2HRH1KDM1A | |
| Hydrochloric Acid SCHEMBL8195730 | 0.99 | SLC6A1 (0.80) | SLC6A1DRD2HRH1 | |
| Hydrochloric Acid SCHEMBL8195734 | 0.99 | SLC6A1 (0.80) | SLC6A1DRD2HRH1 | |
| SCHEMBL9084697 | 0.90 | SLC6A1 (1.00) | SLC6A1 | |
| SCHEMBL9084381 | 0.90 | SLC6A1 (1.00) | SLC6A1 | |
| SCHEMBL7608009 | 0.89 | FPR2 (0.70) | SLC6A1DRD2HRH1 | |
| SCHEMBL7608016 | 0.89 | FPR2 (0.70) | SLC6A1DRD2HRH1 | |
| Hydrochloric Acid SCHEMBL8859095 | 0.89 | SLC6A1 (0.98) | SLC6A1 | |
| Hydrochloric Acid SCHEMBL8859093 | 0.89 | SLC6A1 (0.98) | SLC6A1 | |
| SCHEMBL8936291 | 0.89 | SLC6A1 (0.66) | SLC6A1DRD2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1135129-A1 | USE OF N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INDICATIONS RELATED TO ANGIOGENESIS | NOVO NORDISK A/S (DK) | 2001-09-26 | — | — | EP | claimed |
| WO-2000032193-A1 | USE OF N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INDICATIONS RELATED TO ANGIOGENESIS | NOVO NORDISK A/S (DK) | 2000-06-08 | — | — | WO | claimed |
| EP-0738262-B1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK AS (DK) | 2000-04-19 | — | — | EP | claimed |
| US-6043239-A | N-SUBSTITUTED AZAHETEROCYCLIC CARBOXYLIC ACIDS AND ESTERS THEREOF IN WHICH A SUBSTITUTED ALKYL CHAIN FORMS PART OF THE N-SUBSTITUENT; TREATMENT OF PAINFUL, HYPERALGESIC AND/OR INFLAMMATORY CONDITIONS | NOVO NORDISK A/S (DK) | 2000-03-28 | — | — | US | claimed |
| US-5795888-A | ANALGESICS, ANTIINFLAMMATORY AGENTS, ANTIDIABETIC AGENTS | NOVO NORDISK A/S (DK) | 1998-08-18 | — | — | US | claimed |
| EP-0738262-A1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1996-10-23 | — | — | EP | claimed |
| WO-1995018793-A1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1995-07-13 | — | — | WO | claimed |
| US-20020045610-A1 | Use of N-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesis | LUBRIZOL CORPORATION, THE | 2002-04-18 | — | — | US | disclosed |
| EP-1135129-A1 | USE OF N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INDICATIONS RELATED TO ANGIOGENESIS | NOVO NORDISK A/S (DK) | 2001-09-26 | — | — | EP | disclosed |
| WO-2000032193-A1 | USE OF N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INDICATIONS RELATED TO ANGIOGENESIS | NOVO NORDISK A/S (DK) | 2000-06-08 | — | — | WO | disclosed |
| EP-0869777-A1 | NOVEL METHOD | NOVO NORDISK A/S (DK) | 1998-10-14 | — | — | EP | disclosed |
| US-5741791-A | ADMINISTERING COMPOUNDS WHICH INHIBIT SECRETION, CIRCULATION OR EFFECT OF INSULIN ANTAGONIZING PEPTIDES; CAN BE USED TO TREAT NON-INSULIN-DEPENDENT DIABETES MELLITUS | NOVO NORDISK A/S (DK) | 1998-04-21 | — | — | US | disclosed |
| WO-1997022338-A1 | NOVEL METHOD | NOVO NORDISK A/S (DK) | 1997-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045610-A1 | Use of N-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesis | VEGFA, KDR, FLT4 | SLC6A1 3399/4885DRD2 2668/4885HRH1 1274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.